Related Experiment Video

Updated: Aug 8, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

[Indicators of cellular immunity in patients with multiple sclerosis]

A N Dziuba, V M Frolov, I S Gaĭdash

    Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952)
    |January 1, 1992
    PubMed

    Insights

    This study examined 111 multiple sclerosis patients, finding cellular immunity alterations during exacerbation. Immunocorrective therapy helped stabilize immune function in these patients.

    Area of Science:

    • Immunology
    • Neurology
    • Clinical Medicine

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Cellular immunity plays a critical role in the pathogenesis of MS.
    • Understanding immune system changes during MS exacerbation is crucial for effective treatment.

    Purpose of the Study:

    • To investigate alterations in cellular immunity in patients with multiple sclerosis during exacerbation.
    • To evaluate the impact of immunocorrective therapy on cellular immunity in MS patients.

    Main Methods:

    • Clinical and functional examinations were performed on 111 MS patients.
    • Blood samples were analyzed to assess cellular immunity markers.
    • Examinations were conducted twice: upon hospital admission and post-immunocorrective therapy.

    Main Results:

    • Patients exhibited significant alterations in cellular immunity during MS exacerbation.
    • A decline in suppressor cells and an increase in B lymphocytes were observed during exacerbation.
    • Immunocorrective therapy resulted in the stabilization of immune function, indicating a positive therapeutic effect.

    Conclusions:

    • Cellular immunity is significantly altered during multiple sclerosis exacerbations.
    • Immunocorrective therapy demonstrates potential in stabilizing immune dysregulation in MS.
    • Further research into targeted immunotherapies for MS is warranted.

    More Related Videos

    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

    Published on: September 9, 2022

    Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens06:03

    Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

    Published on: September 20, 2024

    Related Concept Videos

    T Cell Types and Functions01:24

    T Cell Types and Functions

    When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
    Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...